Table 6.
Baseline Characteristics of High-Risk Group under 3-Monthly and 6-Monthly Surveillance from Year 1 after Treatment
| Variable | Original set | Matched set | ||||
|---|---|---|---|---|---|---|
|
|
|
|||||
| 3-Monthly surveillance (n=96) | 6-Monthly surveillance (n=87) | p-value* | 3-Monthly surveillance (n=62) | 6-Monthly surveillance (n=62) | p-value* | |
| Age, yr | 67 (61–73) | 66 (61–70) | 0.20 | 66 (59–71) | 66 (61–72) | 0.62 |
| Male sex | 69 (71.9) | 51 (58.6) | 0.08 | 44 (71.0) | 37 (59.7) | 0.26 |
| Etiology | 0.81 | 0.89 | ||||
| HBV | 47 (49.0) | 47 (54.0) | 33 (53.2) | 32 (51.6) | ||
| HCV | 26 (27.1) | 24 (27.6) | 15 (24.2) | 17 (27.4) | ||
| HBV+HCV | 1 (1.0) | 1 (1.2) | 0 (0.0) | 1 (1.6) | ||
| Others† | 22 (22.9) | 15 (17.2) | 14 (22.6) | 12 (19.4) | ||
| CTP score | 5 (5–6) | 5 (5–6) | 0.56 | 5 (5–6) | 5 (5–6) | 0.82 |
| MELD score | 10 (9–11) | 10 (9–11) | 0.28 | 10 (9–11) | 10 (9–11) | 0.76 |
| AST, U/L | 47 (33–64) | 47 (34–57) | 0.53 | 47 (34–56) | 47 (35–55) | 0.65 |
| ALT, U/L | 40 (29–65) | 34 (24–48) | 0.008 | 42 (30–57) | 34 (24–49) | 0.03 |
| Albumin, g/dL | 3.9 (3.50–4.1) | 3.8 (3.5–4.0) | 0.32 | 3.8 (3.5–4.1) | 3.8 (3.5–4.1) | 0.94 |
| Total bilirubin, mg/dL | 1.1 (0.9–1.4) | 1.2 (1.0–1.5) | 0.49 | 1.2 (0.9–1.5) | 1.2 (1.0–1.4) | 0.97 |
| Creatinine, mg/dL | 0.9 (0.8–1.0) | 0.9 (0.8–1.0) | 0.74 | 0.9 (0.8–1.0) | 0.9 (0.8–1.0) | 0.81 |
| PT INR | 1.2 (1.1–1.3) | 1.2 (1.2–1.3) | 0.26 | 1.2 (1.2–1.3) | 1.2 (1.2–1.3) | 0.88 |
| Platelet, ×103/μL | 109 (74–160) | 91 (65–123) | 0.02 | 93 (71–121) | 93 (68–126) | 0.76 |
| AFP, ng/mL | 11.4 (5.5–55.4) | 13.0 (6.0–32.5) | 0.82 | 9.0 (5.1–21.0) | 13.9 (5.9–34.0) | 0.25 |
| Tumor size, cm | 2.1 (1.6–2.8) | 2.1 (1.8–2.9) | 0.78 | 2.0 (1.5–2.8) | 2.1 (1.7–2.9) | 0.61 |
| Tumor number | 0.70 | 1.00 | ||||
| 1 | 86 (89.6) | 74 (85.1) | 53 (85.5) | 54 (87.1) | ||
| 2 | 8 (8.3) | 11 (12.6) | 7 (11.3) | 6 (9.7) | ||
| 3 | 2 (2.1) | 2 (2.3) | 2 (3.2) | 2 (3.2) | ||
| BCLC stage | 1.00 | 1.00 | ||||
| 0 | 37 (38.5) | 34 (39.1) | 25 (40.3) | 26 (41.9) | ||
| A | 59 (61.5) | 53 (60.9) | 37 (59.7) | 36 (58.1) | ||
| Treatment method | 0.88 | 1.00 | ||||
| RFA | 72 (75.0) | 67 (77.0) | 47 (75.8) | 48 (77.4) | ||
| Resection | 24 (25.0) | 20 (23.0) | 15 (24.2) | 14 (22.6) | ||
Data are presented as median (interquartile range) or number (%).
HBV, hepatitis B virus; HCV, hepatitis C virus; CTP, Child-Turcotte-Pugh; MELD, Model for End-Stage Liver Disease; AST, aspartate aminotransferase; ALT, alanine aminotransferase; PT INR, international normalized ratio for prothrombin time; AFP, alpha-fetoprotein; BCLC, Barcelona Clinic Liver Cancer; RFA, radiofrequency ablation.
*
p-value estimated by chi-square test or Fisher exact test for categorical variables and Mann-Whitney U test;
†
Other causes included alcohol, non-alcoholic fatty liver disease, primary biliary cholangitis, and autoimmune hepatitis.